Eva Maria Gerstl

In pediatric diabetes, insulin pump therapy is associated with less acute complications but inpatient pump education may lead to more hospital days. We investigated the number of hospital days associated with pump vs. injection therapy between 2009 and 2018 in 48,756 patients with type 1 diabetes < 20 years of age from the German Diabetes Prospective Follow-up Registry (DPV). Analyses were performed separately for hospitalizations at diagnosis (hierarchical linear models adjusted for sex, age, and migration), and for hospitalizations in the subsequent course of the disease (hierarchical Poisson models stratified by sex, age, migration, and therapy switch). At diagnosis, the length of hospital stay was longer with pump therapy than with injection therapy (mean estimate with 95% CI: 13.6 [13.3–13.9] days vs. 12.8 [12.5–13.1] days, P < 0.0001), whereas during the whole follow-up beyond diagnosis, the number of hospital days per person-year (/PY) was higher with injection therapy than with pump therapy (4.4 [4.1–4.8] vs. 3.9 [3.6–4.2] days/PY), especially for children under 5 years of age (4.9 [4.4–5.6] vs. 3.5 [3.1–3.9] days/PY).Conclusions: Even in countries with hospitalizations at diabetes diagnosis of longer duration, the use of pump therapy is associated with a reduced number of hospital days in the long-term. What is known:• In pediatric diabetes, insulin pump therapy is associated with better glycemic control and less acute complications compared with injection therapy.• However, pump therapy implies more costs and resources for education and management.What is new:• Even in countries where pump education is predominantly given in an inpatient setting, the use of pump therapy is associated with a reduced number of hospital days in the long-term.• Lower rates of hospitalization due to acute complications during the course of the disease counterbalance longer hospitalizations due to initial pump education